What is the share price of Tatva Chintan Pharma Chem Ltd (TATVA) today?
The share price of TATVA as on 21st March 2025 is ₹702.70. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Tatva Chintan Pharma Chem Ltd (TATVA) share?
The past returns of Tatva Chintan Pharma Chem Ltd (TATVA) share are- Past 1 week: 7.25%
- Past 1 month: 1.64%
- Past 3 months: -16.66%
- Past 6 months: -29.87%
- Past 1 year: -39.59%
- Past 3 years: -68.80%
- Past 5 years: -69.61%
What are the peers or stocks similar to Tatva Chintan Pharma Chem Ltd (TATVA)?
The peers or stocks similar to Tatva Chintan Pharma Chem Ltd (TATVA) include:What is the dividend yield % of Tatva Chintan Pharma Chem Ltd (TATVA) share?
The current dividend yield of Tatva Chintan Pharma Chem Ltd (TATVA) is 0.28.What is the market cap of Tatva Chintan Pharma Chem Ltd (TATVA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Tatva Chintan Pharma Chem Ltd (TATVA) is ₹1643.76 Cr as of 21st March 2025.What is the 52 week high and low of Tatva Chintan Pharma Chem Ltd (TATVA) share?
The 52-week high of Tatva Chintan Pharma Chem Ltd (TATVA) is ₹1320 and the 52-week low is ₹621.What is the PE and PB ratio of Tatva Chintan Pharma Chem Ltd (TATVA) stock?
The P/E (price-to-earnings) ratio of Tatva Chintan Pharma Chem Ltd (TATVA) is 54.18. The P/B (price-to-book) ratio is 2.23.Which sector does Tatva Chintan Pharma Chem Ltd (TATVA) belong to?
Tatva Chintan Pharma Chem Ltd (TATVA) belongs to the Materials sector & Specialty Chemicals sub-sector.How to buy Tatva Chintan Pharma Chem Ltd (TATVA) shares?
You can directly buy Tatva Chintan Pharma Chem Ltd (TATVA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Tatva Chintan Pharma Chem Ltd
TATVA Share Price
702.703.19% (+21.70)
TATVA Share Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
TATVA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 114.87 | 2.23 | 0.28% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 29.27 | 3.33 | 1.42% |
TATVA Analyst Ratings & Forecast
Detailed Forecast 67%
Analysts have suggested that investors can buy this stock
from 3 analysts
Price Upside
Earnings Growth
Rev. Growth
TATVA Company Profile
Tatva Chintan Pharma Chem is engaged in the manufacturing business of chemical products.
Investor Presentation
View olderTATVA Similar Stocks (Peers)
Compare with peersFLUOROCHEM
PE Ratio
99.47
1Y Return
27.05%
Buy Reco %
80.00
NAVINFLUOR
PE Ratio
77.85
1Y Return
37.61%
Buy Reco %
76.00
VINATIORGA
PE Ratio
51.43
1Y Return
0.20%
Buy Reco %
61.54
AKZOINDIA
PE Ratio
36.03
1Y Return
38.70%
Buy Reco %
50.00
AARTIIND
PE Ratio
35.45
1Y Return
37.20%
Buy Reco %
58.82
TATVA Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
TATVA Stock Summary · January 2025
In Q3 FY2025, the company faced mixed results, with revenue growth in specific segments like Electrolyte Salts and Phase Transfer Catalysts, while overall profitability declined due to rising costs and operational challenges. Despite subdued demand, signs of market recovery and successful onboarding of new multinational customers in the PTC segment offer optimism for future growth. The commitment to research and development, particularly in high-purity semiconductor materials and agro products, positions the company to capitalize on emerging opportunities. However, logistical hurdles and the cyclical nature of the automotive industry necessitate a focus on operational efficiency and strategic investments to enhance margins and stabilize revenue streams moving forward.
Key Points on TATVA Stock Performance
TATVA Stock Growth Drivers
7Financial Performance and Revenue Growth
The company reported a revenue from operations of Rs. 859 million, showing a 2% year-on-year
New Customer Acquisition and Market Expansion
The company successfully onboarded two new multinational customers in the PTC segment, with commercial business
TATVA Stock Challenges
5Declining Financial Performance
Tatva Chintan Pharma Chem Limited has reported a significant decline in key financial metrics. In
Challenges in Specific Product Segments
The Structure-Directing Agents (SDAs) segment has faced notable challenges, with revenue reflecting a 15% decline
TATVA Forecasts
Price
Revenue
Earnings
TATVA Share Price Forecast
2024
Current
₹702.70
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2024
Current
₹702.70
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
TATVA Company Revenue Forecast
2024
Current
₹401.01
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
2024
Current
₹401.01
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
TATVA Stock EPS (Earnings Per Share) Forecast
2024
Current
₹13.32
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—
All values in ₹
2024
Current
₹13.32
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—
All values in ₹
TATVA
Income
Balance Sheet
Cash Flow
Annual Normal View
TATVA Income Statement
Annual Normal View
| Financial Year | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 137.29 | 207.55 | 264.62 | 305.56 | 442.54 | 429.35 | 401.01 | 379.24 | ||||||||
Raw Materials | 74.16 | 118.57 | 148.61 | 156.06 | 258.17 | 220.39 | 182.36 | 332.25 | ||||||||
| Power & Fuel Cost | 4.65 | 6.25 | 8.96 | 9.92 | 22.62 | 23.61 | 34.78 | |||||||||
| Employee Cost | 12.27 | 16.31 | 20.53 | 23.80 | 30.81 | 41.21 | 54.76 | |||||||||
| Selling & Administrative Expenses | 16.15 | 25.04 | 27.15 | 30.70 | 51.99 | 44.94 | 39.13 | |||||||||
| Operating & Other expenses | 5.45 | 6.02 | 2.72 | 13.20 | -38.46 | 36.27 | 14.08 | |||||||||
EBITDA | 24.61 | 35.36 | 56.65 | 71.88 | 117.41 | 62.93 | 75.90 | 46.99 | ||||||||
| Depreciation/Amortization | 2.95 | 4.02 | 4.79 | 6.73 | 8.18 | 9.56 | 25.61 | 26.63 | ||||||||
| PBIT | 21.66 | 31.34 | 51.86 | 65.15 | 109.23 | 53.37 | 50.29 | 20.36 | ||||||||
| Interest & Other Items | 2.63 | 3.95 | 4.27 | 4.45 | 5.11 | 8.60 | 6.73 | 1.11 | ||||||||
| PBT | 19.03 | 27.39 | 47.59 | 60.70 | 104.12 | 44.77 | 43.56 | 19.25 | ||||||||
| Taxes & Other Items | 6.75 | 6.85 | 9.81 | 8.43 | 8.25 | -0.70 | 13.22 | 4.94 | ||||||||
| Net Income | 12.28 | 20.54 | 37.78 | 52.27 | 95.87 | 45.47 | 30.34 | 14.31 | ||||||||
| EPS | 6.11 | 10.23 | 18.81 | 26.02 | 45.38 | 20.51 | 13.32 | 6.12 | ||||||||
| DPS | 0.00 | 0.00 | 0.00 | 5.00 | 2.00 | 2.00 | 2.00 | 2.00 | ||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.19 | 0.04 | 0.10 | 0.15 | 0.33 |
TATVA Company Updates
TATVA Past Performance & Peer Comparison
Comparing 3 stocks from
MaterialsSpecialty Chemicals
Compare valuation on Screener
MaterialsSpecialty Chemicals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Tatva Chintan Pharma Chem Ltd | 54.18 | 2.23 | 0.28% |
| Gujarat Fluorochemicals Ltd | 99.47 | 7.29 | 0.08% |
| Navin Fluorine International Ltd | 77.85 | 8.84 | 0.35% |
| Vinati Organics Ltd | 51.43 | 6.75 | 0.44% |
TATVA Stock Price Comparison
Compare TATVA with any stock or ETFCompare TATVA with any stock or ETF
TATVA
TATVA Shareholdings
TATVA Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
TATVA Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
TATVA Shareholding Pattern
TATVA Shareholding History
Foreign Institutions
Mutual Funds Invested in TATVA
A list of mutual funds holding the stock, ranked on the basis of Market-cap held which is calculated as the value of stock held in the portfolio divided by its market cap
Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Tatva Chintan Pharma Chem Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 3.2568% | Percentage of the fund’s portfolio invested in the stock 0.40% | Change in the portfolio weight of the stock over the last 3 months -0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 60/67 (-2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.0576% | Percentage of the fund’s portfolio invested in the stock 0.25% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 28/128 (+1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.7068% | Percentage of the fund’s portfolio invested in the stock 0.75% | Change in the portfolio weight of the stock over the last 3 months -0.07% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 39/56 (-1) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing TATVA stock
Looks like this stock is not in any smallcase yet.
TATVA Events
TATVA Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
TATVA Upcoming Dividends
No upcoming dividends are available
TATVA Past Dividends
Cash Dividend
Ex DateEx DateSep 6, 2024
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Sep 6, 2024
Cash Dividend
Ex DateEx DateSep 8, 2023
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Sep 8, 2023
Cash Dividend
Ex DateEx DateSep 8, 2022
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Sep 8, 2022
TATVA Stock News & Opinions
Articles & Videos
Earnings
Tatva Chintan Pharma Chem consolidated net profit declines 95.95% in the December 2024 quarter
Net profit of Tatva Chintan Pharma Chem declined 95.95% to Rs 0.14 crore in the quarter ended December 2024 as against Rs 3.46 crore during the previous quarter ended December 2023. Sales rose 2.01% to Rs 85.90 crore in the quarter ended December 2024 as against Rs 84.21 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales85.9084.21 2 OPM %8.2213.05 - PBDT6.6911.83 -43 PBT-0.245.24 PL NP0.143.46 -96 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Tatva Chintan Pharma Chem declare Quarterly Result
Tatva Chintan Pharma Chem will hold a meeting of the Board of Directors of the Company on 28 January 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Tatva Chintan Pharma Chem reports consolidated net loss of Rs 0.66 crore in the September 2024 quarter
Net loss of Tatva Chintan Pharma Chem reported to Rs 0.66 crore in the quarter ended September 2024 as against net profit of Rs 7.78 crore during the previous quarter ended September 2023. Sales declined 13.63% to Rs 83.49 crore in the quarter ended September 2024 as against Rs 96.67 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales83.4996.67 -14 OPM %6.6820.94 - PBDT5.7917.99 -68 PBT-1.0211.21 PL NP-0.667.78 PL Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Tatva Chintan Pharma Chem to discuss results
Tatva Chintan Pharma Chem will hold a meeting of the Board of Directors of the Company on 25 October 2024.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Tatva Chintan Pharma Chem AGM scheduled
Tatva Chintan Pharma Chem announced that the Annual General Meeting (AGM) of the company will be held on 20 September 2024.Powered by Capital Market - Live
6 months agoCapital Market - Live
Purple Finance Ltd leads losers in ‘B’ group
7 months agoBusiness Standard
Tatva Chintan Pharma Chem consolidated net profit declines 45.16% in the June 2024 quarter
7 months agoBusiness Standard
Earnings
Tatva Chintan Pharma Chem consolidated net profit declines 45.16% in the June 2024 quarter
Net profit of Tatva Chintan Pharma Chem declined 45.16% to Rs 5.21 crore in the quarter ended June 2024 as against Rs 9.50 crore during the previous quarter ended June 2023. Sales declined 7.78% to Rs 105.46 crore in the quarter ended June 2024 as against Rs 114.36 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales105.46114.36 -8 OPM %11.9718.66 - PBDT13.4719.43 -31 PBT6.8113.42 -49 NP5.219.50 -45 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Tatva Chintan Pharma Chem to convene board meeting
Tatva Chintan Pharma Chem will hold a meeting of the Board of Directors of the Company on 24 July 2024.Powered by Capital Market - Live
8 months agoCapital Market - Live
Tatva Chintan Q4 Results Review - Revenue May Rise 25% With Expansion In Margin: ICICI Securities
10 months agoBloomberg Quint
Over the last 5 years, revenue has grown at a yearly rate of 14.08%, vs industry avg of 6.08%
Over the last 5 years, market share increased from 0.37% to 0.45%
Over the last 5 years, net income has grown at a yearly rate of 8.11%, vs industry avg of -1.24%